Biotech News

Senseonics Holdings, Inc. Reports Third Quarter 2026 Financial Results

Senseonics (SENS)SenseonicsEarnings

Senseonics Holdings, Inc. (NASDAQ: SENS), a diabetes company redefining continuous glucose monitoring (CGM) with long-term implantable sensing technology, today announced third quarter 2026 financial results and provided a business update.

Related news

Senseonics

Implantable Glucose Monitoring Senseonics develops long-term implantable continuous glucose-monitoring systems for people with diabetes. Its fluorescence-based sensor is placed under the skin rather than replaced every one to two weeks like conventional transcutaneous sensors. Eversense 365 Eversense 365 is designed to provide up to one...

Recent company news

Stock data

Close
8.91 USD
Market cap
358.63M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States